2 results
Approved WMOCompleted
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
Approved WMOCompleted
To determine the Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 of CriPec® docetaxel monotherapy in subjects with ovarian cancer who are resistant to prior platinum-based therapy.